Sagimet Biosciences (SGMT) Amortizatization of Intangibles (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Amortizatization of Intangibles of $140000.0 for Q1 2026, down 73.83% year-over-year from $535000.0 in Q1 2025, and up 146.67% quarter-over-quarter from -$300000.0 in Q4 2025.
Powered by 
Analysis
Sagimet Biosciences (SGMT) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $140000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 73.83% year-over-year to $140000.0; the TTM figure through Mar 2026 stood at -$6000.0 (down 100.38% YoY), while the FY2025 annual figure was $389000.0, down 68.95% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $140000.0, up from -$300000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $535000.0 in Q1 2025, with the low at -$300000.0 in Q4 2025.
- The 5-year median for Amortizatization of Intangibles is $85500.0 (2022), against an average of $142142.9.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles surged 11825.0% in 2024, then slumped 635.71% in 2025.
- Sagimet Biosciences' Amortizatization of Intangibles stood at $83000.0 in 2022, then sank by 102.41% to -$2000.0 in 2023, then soared by 2900.0% to $56000.0 in 2024, then plunged by 635.71% to -$300000.0 in 2025, then soared by 146.67% to $140000.0 in 2026.
- Business Quant data shows SGMT's Amortizatization of Intangibles at $140000.0 in Q1 2026, -$300000.0 in Q4 2025, and -$72000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Sagimet Biosciences | 579.48 Mn | 579.48 Mn | - | 17,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17,000.00 |
| Mar 31, 2026 | 140,000.00 |
| Dec 31, 2025 | -300,000.00 |
| Sep 30, 2025 | -72,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Mar 31, 2025 | 535,000.00 |
| Dec 31, 2024 | 56,000.00 |
| Sep 30, 2024 | 527,000.00 |
| Jun 30, 2024 | 477,000.00 |
| Mar 31, 2024 | 193,000.00 |
| Dec 31, 2023 | -2,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Mar 31, 2023 | 35,000.00 |
| Dec 31, 2022 | 83,000.00 |
| Sep 30, 2022 | 88,000.00 |